Jeffrey A. Barnes, Ph.D.

2004 University of Illinois, Urbana-Champaign, Urbana-Champaign, IL 
"Jeffrey Barnes"
Mean distance: 17.58 (cluster 32)


Sign in to add mentor
Martha Ulbrick Gillette grad student 2004 UIUC
 (Conservation of Timeless in the mammalian circadian clock.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Haydu JE, Maron JS, Redd RA, et al. (2022) Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Advances
Soumerai JD, Mato AR, Dogan A, et al. (2021) Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet. Haematology. 8: e879-e890
Soumerai JD, Mato AR, Carter J, et al. (2020) Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax. Journal of Clinical Oncology. 38: 8006-8006
Abramson JS, Irwin KE, Frigault MJ, et al. (2019) Successful anti-CD19 CAR T-cell therapy in HIV-infected patients with refractory high-grade B-cell lymphoma. Cancer
Abramson JS, Arnason JE, LaCasce AS, et al. (2019) Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma. Blood
Karschnia P, Jordan JT, Forst DA, et al. (2019) Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T-cells. Blood
Karmali R, Abramson JS, Stephens DM, et al. (2019) Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report. Journal of Clinical Oncology. 37: 7542-7542
Karmali R, Abramson JS, Stephens DM, et al. (2019) Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation Blood. 134: 3990-3990
Barnes JA, Redd R, Fisher DC, et al. (2018) Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. Hematological Oncology
Abramson JS, Redd RA, Barnes JA, et al. (2018) A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma Blood. 132: 1654-1654
See more...